Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial
The base-case results indicate that empagliflozin + SoC is a dominant strategy compared with the current SoC for the management of CKD in France. Empagliflozin + SoC would have a positive impact on patients with CKD by slowing CKD progression and leading to the prevention of kidney failure events on top of all-stages CKD complications.
Authors
- Marine Sivignon
- J. Tardu
- Harinala Groyer
- Ziad A. Massy (ORCID: https://orcid.org/0000-0001-5771-5996)
- R. Supiot (ORCID: https://orcid.org/0000-0002-8416-3063)
- Nicolas Virely
- Pierre Lévy (ORCID: https://orcid.org/0000-0001-7565-2255)
- Anastasia Ustyugova
- Denis San
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris Sciences et Lettres (FR)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Boehringer Ingelheim (France) (FR)
- Paññāsāstra University of Cambodia (KH)
- Association pour l'Utilisation du Rein Artificiel (FR)
- Université Paris Dauphine-PSL (FR)
Publication Details
- Journal
- Clinical Drug Investigation
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1007/s40261-024-01398-4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Oxford
- Boehringer Ingelheim France